Atidon Tablet (Domperidone 10 mg) – Oral Tablet

1. About Atidon Tablet (Domperidone 10 mg)

Atidon Tablet contains Domperidone 10 mg, a peripheral dopamine D2 receptor antagonist with prokinetic and antiemetic properties. Domperidone accelerates gastric emptying, reduces nausea and vomiting, and improves symptoms of upper GI motility disorders — including the delayed gastric emptying that commonly complicates long-standing T2DM (diabetic gastroparesis).

Unlike metoclopramide, domperidone does not readily penetrate the blood-brain barrier, resulting in far fewer central nervous system side effects. This makes it the preferred prokinetic for longer-term management of diabetic gastroparesis in ambulatory patients. The main safety concern unique to domperidone is QT interval prolongation, requiring cardiac monitoring in at-risk patients.

2. Mechanism of Action

Domperidone competitively blocks peripheral dopamine D2 and D3 receptors in the gastric antrum, duodenum, and the chemoreceptor trigger zone (CTZ). Peripheral D2 blockade in the GI tract enhances antroduodenal coordination and increases lower oesophageal sphincter pressure, accelerating gastric emptying. CTZ blockade (at the blood-brain barrier) provides antiemetic effect. Because the CTZ lies outside the blood-brain barrier, domperidone can access this area without significant CNS penetration — explaining its favourable EPS profile compared to metoclopramide.

3. Indications

• Diabetic gastroparesis — delayed gastric emptying in T2DM with nausea, vomiting, early satiety, bloating
• Functional dyspepsia — postprandial fullness, epigastric discomfort, bloating
• Nausea and vomiting — including from medications, functional disorders
• Gastroesophageal reflux disease (GERD) — adjunct to PPI therapy for motility component
• Nausea from dopaminergic drugs — levodopa, bromocriptine, apomorphine

4. Dosage and Administration

Adults: 10 mg three times daily, taken 15–30 minutes before meals (and at bedtime if nocturnal symptoms). Maximum 30 mg/day. Maximum recommended duration: 1 week for routine dyspepsia/nausea per EMA 2014 guidance. Specialist supervision required for extended use in diabetic gastroparesis.

Elderly: Lowest effective dose; baseline ECG recommended before use due to higher cardiac comorbidity risk. Hepatic impairment: Avoid in severe hepatic impairment. Renal impairment: Dose frequency reduction may be needed in severe renal failure.

5. Contraindications

• Known QT prolongation or congenital long QT syndrome
• Concurrent strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, ritonavir, grapefruit) — contraindicated combination
• Severe hepatic impairment
• GI haemorrhage, mechanical obstruction, or perforation
• Prolactinoma (prolactin-secreting pituitary tumour)
• Hypersensitivity to domperidone

6. Warnings and Precautions

QT Prolongation — Key Safety Issue: Domperidone prolongs QTc interval and is associated with rare cases of serious ventricular arrhythmias (torsades de pointes) and sudden cardiac death, particularly at doses >30 mg/day and in elderly patients. Risk assessment: baseline ECG in cardiac patients; avoid with other QT-prolonging drugs and strong CYP3A4 inhibitors.

Diabetic patients: Cardiac autonomic neuropathy in T2DM alters QT dynamics. Baseline ECG is especially important before domperidone initiation in T2DM with CAN.

Hyperprolactinaemia: Chronic domperidone use elevates prolactin — may cause galactorrhoea, gynecomastia, menstrual irregularities, impotence. Monitor prolactin if symptomatic.

7. Side Effects

Common: Dry mouth, headache, GI effects, elevated prolactin (galactorrhoea, menstrual irregularities).

Uncommon: QT prolongation, anxiety, libido changes, drowsiness.

Rare: Torsades de pointes, sudden cardiac death (high dose/elderly), EPSE (rare vs metoclopramide), severe allergic reaction.

8. Drug Interactions

• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, HIV PIs, grapefruit): Contraindicated — markedly increase domperidone AUC and QT risk
• QT-prolonging drugs (macrolides, fluoroquinolones, antipsychotics, amiodarone, TCA): Additive QT effect — avoid combination or monitor closely
• Anticholinergics: Antagonise domperidone's prokinetic effect
• Opioids: Reduce gastric motility — antagonise domperidone

9. Domperidone in Diabetic Gastroparesis Management

Diabetic gastroparesis is a challenging complication requiring multidisciplinary management. Domperidone is one of only two prokinetics (with metoclopramide) with substantial clinical evidence in diabetic gastroparesis. Current Bangladesh and international management approach: (1) Optimise glycaemic control — hyperglycaemia itself delays gastric emptying; (2) Dietary modification — small, frequent, low-fat, low-fibre meals; (3) Prokinetic therapy — domperidone 10 mg TDS before meals (specialist-supervised for >1 week); (4) Antiemetic support for nausea; (5) Nutritional support if severe weight loss.

10. Storage

• Below 30°C, cool and dry, protected from light. Original blister. Out of reach of children.

Frequently Asked Questions (FAQ)

Q1: How long can I take Atidon Tablet (Domperidone) for?

The European Medicines Agency (EMA) 2014 review recommended limiting domperidone to a maximum of 1 week at 10 mg three times daily for routine nausea, vomiting, and dyspepsia due to QT prolongation risk. For chronic conditions like diabetic gastroparesis, longer use is sometimes necessary under specialist supervision with cardiac monitoring (baseline ECG, periodic QTc assessment). Never self-extend domperidone beyond 1 week without medical review. If prolonged prokinetic therapy is needed, your gastroenterologist or endocrinologist will reassess the risk-benefit balance and monitoring plan.

Q2: Can Atidon (Domperidone) help with nausea from metformin or other diabetes medicines?

Yes — domperidone's prokinetic and antiemetic effects are useful for GI side effects from diabetes medications. Metformin commonly causes nausea, vomiting, and GI discomfort (particularly on initiation or dose escalation). Domperidone can relieve these symptoms by accelerating gastric emptying and suppressing nausea via CTZ blockade. It is also useful for nausea associated with GLP-1 receptor agonists (liraglutide, semaglutide) — which commonly cause dose-dependent nausea through central GLP-1 receptor activation. However, domperidone does not address the underlying cause of medication-induced nausea — dose adjustment or gradual titration of the offending drug remains the primary approach.

Q3: Is Atidon Domperidone safe with my heart blood pressure medicines?

This requires careful review. Many antihypertensives and cardiac medications can interact with domperidone: (1) Calcium channel blockers (diltiazem, verapamil): These are CYP3A4 inhibitors and also have QT effects — increased domperidone levels; (2) Beta-blockers: Generally safe — no significant interaction with domperidone; (3) ACE inhibitors/ARBs: Generally safe; (4) Amiodarone, sotalol, quinidine: Significantly prolong QT — avoid combination with domperidone; (5) Digoxin: No direct interaction but both can affect cardiac conduction. Always inform your prescriber of all medications including domperidone before starting.

Q4: What is the difference between Atidon and Maxolon (Metoclopramide) for gastroparesis?

Both domperidone (Atidon) and metoclopramide (Maxolon) are D2 antagonist prokinetics with evidence in gastroparesis, but they differ importantly: (1) CNS effects: Metoclopramide crosses the blood-brain barrier → extrapyramidal side effects (acute dystonia, tardive dyskinesia with long-term use), sedation, depression. Domperidone has minimal CNS penetration → far lower EPS risk. (2) Cardiac: Domperidone has greater QT prolongation risk than metoclopramide. (3) Efficacy: Comparable for gastric emptying acceleration. (4) Duration: Domperidone safer for longer-term use (neurologically); metoclopramide should not be used >12 weeks due to tardive dyskinesia risk. Domperidone is generally preferred for longer-term use in diabetic gastroparesis unless cardiac risk is a concern.